AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.
Research Site, Wakefield, United Kingdom
Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B, Atlanta, Georgia, United States
Baltimore VA Medical Center (Site 1258), 10 N. Greene St., Baltimore, Maryland, United States
Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.